GlassScriptPhysician profile
Muhammad A Ahmad
NPI 1811125339
$6,200.37
in general payments reported to CMS, 2019-2025
20 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $385 · 2021: $1,223 · 2022: $259 · 2023: $666 · 2024: $1,554 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,936.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,171.30 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,404.64 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Phathom Pharmaceuticals, INC. | $290.49 | 2024-2025 | Voquezna |
| Genzyme Corporation | $200.83 | 2021-2025 | |
| Lilly USA, LLC | $179.00 | 2019-2025 | Zepbound, Mounjaro |
| Steris Corporation | $157.66 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $125.00 | 2024 | Inpefa |
| Abbvie INC. | $124.98 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $124.77 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $54.79 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $45.07 | 2023-2024 | Aralast |
| Teva Pharmaceuticals USA, INC. | $43.51 | 2020-2021 | |
| Electromed, INC. | $38.35 | 2025 | Smartvest |
| Viatris Specialty LLC | $29.16 | 2025 | Yupelri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $28.67 | 2025 | Brinsupri, Arikayce |
| Verona Pharma, INC. | $24.15 | 2025 | Ohtuvayre |
| Amarin Pharma, INC. | $22.56 | 2019 | |
| Pfizer INC. | $21.92 | 2019 | |
| Amgen INC. | $16.93 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.